bioMérieux 2014 Annual Report

In line with our vision and the actions we have pursued over the last four years, our strategic progress has been remarkable.

With particularly solid fundamentals and the support of its shareholders, bioMérieux is well positioned and can look to the future with confidence.

Division Highlights

• Sales of bioMérieux’s clinical applications increased in 2014 at a sustained pace. They were up by 4.6% at constant exchange rates and scope of consolidation, compared to 3.5% in 2013.
• Industrial microbiological control applications, which represents nearly 20% of consolidated sales, underwent growth of 0.8% with variable results depending on the product range and region.

Regional Highlights

• Encompassing North America and Latin America, the Americas region accounts for 34% of bioMérieux’s total consolidated sales. With the return to a favorable market environment, the region shows significant growth of nearly 7%.
• For the second consecutive year, North American sales grew by nearly 5%.
• The Asia Pacific region represented 18% of consolidated sales. With regional growth reaching 3% for 2014, sales varied from one country to the next and from one product range to another.

Sales & Income

• Sales for the year 2014 amounted to €1.698 billion, compared with €1.588 billion in 2013, representing a 3.8% increase at constant exchange rates and scope of consolidation.
• As expected, contributive operating income before non-recurring items was impacted by significant negative currency effects and additional expenses at the Durham, NC site in the US to improve production conditions. In light of these impacts, it decreased yearon- year to €227 million, representing 13.4% of sales.
• Net income amounted to €136 million, compared to €165 million in 2013, due to a decrease in operating income. It represented 8% of sales for the year.

Download the Full Report: